1. Scrip
  2. >>Business

China's CBMG Aims For Large-Scale CAR-T Capacity

 
• By Emily Hayes

CBMG exec Tony Liu looks to differentiate CAR-T offerings partly based on ability to produce at a large scale in China, at a standard that matches the US.

Video interview

Cellular Biomedicine Group Inc. aims to differentiate its chimeric antigen receptor T cell (CAR-T) therapy development in part by large-scale production in the company's home country, China, CEO Bizuo (Tony) Liu told Scrip’s Emily Hayes in an interview at the Biotech Showcase.

The Shanghai-based immunotherapy and stem cell therapy company announced the week before the J.P. Morgan Healthcare conference and parallel Biotech...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Start-Ups & SMEs

More from Business

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial